Original price was: $38.99.$34.99Current price is: $34.99.
Research Studies
KissPeptin-10 10 mg is supplied at 99%+ purity for in-vitro laboratory research only. Not for human or veterinary use.
Reconstituting this vial? Our free peptide reconstitution calculator converts vial mass and diluent volume into concentration, draw volume and U-100 syringe graduations. Research use only.
KissPeptin-10, a signaling peptide studied in reproductive-axis research (lyophilized). For research use only.
Purity: ≥98% HPLC (see batch COA); identity confirmed by LC-MS. A batch-specific Certificate of Analysis (COA) is available for each lot. For laboratory and research use only. Not for human or animal consumption.
| CAS No. | 374675-21-5 |
|---|---|
| Purity | ≥99% |
| Sequence | Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 |
| Molecular Formula | C63H83N17O14 |
| Molecular Weight | 1302.46 g/mol |
| Synthesis | Solid-phase synthesis |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Applications | KISS1R signaling research, reproductive endocrinology studies, GnRH regulation models |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
Use bacteriostatic water (BAC) at a 1–2 mL volume per vial. Add the solvent slowly down the vial wall, swirl gently — never shake. Refrigerate after reconstitution and use within 30 days. For in-vitro laboratory handling only.
Lyophilized: 36–46°F (refrigerated) for up to 24 months. Reconstituted: keep refrigerated and protect from light; use within 30 days. Avoid repeated freeze-thaw cycles.
Orders placed before 3 PM EST ship the same business day from our USA facility. Tracking is emailed within 24 hours. Plain, discreet packaging. Free shipping on orders over $150.
For Research Use Only · Not for human consumption
For laboratory teams evaluating where to buy Kisspeptin-10 for research, the priority is documentation, compound identity, and research-use-only (RUO) alignment. Kisspeptin-10 is a decapeptide (sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2) with the molecular formula C63H83N17O14 and a molecular weight of approximately 1,302.5 g/mol (CAS 374675-21-5)[1]. It is described in the literature as a ligand of the kisspeptin receptor (KISS1R / GPR54) studied in reproductive-axis research[2].
Researchers evaluating where to buy Kisspeptin-10 for research should review RUO labeling, a batch-specific certificate of analysis (COA), HPLC purity data, LC-MS or comparable identity support, sequence/mass consistency, and lot traceability before procurement. Material discussed here is intended for laboratory research use only and is not for human or veterinary use.
The phrase is addressed as laboratory research-procurement intent — how qualified researchers evaluate a Kisspeptin-10 reference material through documentation, analytical support, and labeling clarity, not personal, clinical, or consumer decision-making.
| Compound name | Kisspeptin-10 |
| CAS number | 374675-21-5 |
| Molecular formula | C63H83N17O14[1] |
| Molecular weight | ≈ 1,302.5 g/mol[1] |
| Sequence | Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 |
| Classification | KISS1R (GPR54) ligand decapeptide[2] |
| Product form | Lyophilized powder |
| Purity target | ≥ 99% (see batch-specific COA) |
| Regulatory status | Research use only — not for human or veterinary use |
Published literature describes kisspeptin within reproductive-axis (hypothalamic-pituitary-gonadal) research via the KISS1R/GPR54 receptor in cell and preclinical models[2][3]. On a research product page this pathway context should remain academic literature interpretation used to define the receptor lane — it is not converted into product-performance language.
A Kisspeptin-10 COA should be reviewed as a batch-specific record, not a marketing statement. Look for compound name, lot number, test date, stated purity, analytical method, identity confirmation, and sequence/mass information. Purity, identity, method, and lot number should be evaluated together.
| Evaluation area | What to review | Why it matters |
|---|---|---|
| RUO labeling | Clear research-use-only language | Separates research procurement from human-use positioning |
| COA availability | Batch-specific certificate for the received lot | Supports lot-level documentation |
| Purity data | HPLC area-percent support for stated purity | Helps evaluate material consistency |
| Identity testing | LC-MS / mass-spec confirmation vs expected mass | Confirms the material matches the listed peptide |
| Lot traceability | Lot number matching across records | Supports research recordkeeping |
HPLC documentation supports purity assessment; LC-MS or mass-spectrometry documentation supports identity confirmation and molecular-mass review[10][11]. For a decapeptide, mass data confirming the observed mass against the expected value are useful alongside HPLC purity data. ICH Q2(R2) describes validation characteristics used to interpret assay, purity, and identity results[7].
Lot traceability connects the product listing, COA, label, and receiving record. ISO/IEC 17025 addresses the competence of testing laboratories, and NIST resources describe how certificates and lot identifiers support traceability[8][9].
| Research-safe statement | Non-compliant version to avoid |
|---|---|
| “Kisspeptin-10 is discussed in published literature on reproductive-axis research.” | “Kisspeptin-10 boosts testosterone or fertility.” |
| “Researchers should review COA and identity data before procurement.” | “Buy Kisspeptin-10 for hormones.” |
| “Greatest Peptides supplies Kisspeptin-10 as a research-use-only material.” | “Greatest Peptides supplies Kisspeptin-10 for treatment.” |
Greatest Peptides supplies Kisspeptin-10 as a research-use-only laboratory material in lyophilized powder form, positioned around a stated ≥99% purity target, batch-specific COA availability, HPLC/LC-MS documentation, lot-level traceability, and transparent RUO labeling. Products are not intended for human or animal consumption, diagnostic, therapeutic, clinical, or veterinary use.
Published kisspeptin literature spans reproductive-neuroendocrinology and KISS1R/GPR54 receptor research models[2][3]. Model-specific findings should not be generalized or interpreted as use guidance for research-use-only materials.
Compound profile
Kisspeptin-10 in one paragraph
Kisspeptin-10 is the C-terminal decapeptide shared by every member of the kisspeptin family, a set of peptides cut from a single precursor encoded by the KISS1 gene and circulating in several lengths that all terminate in the same ten residues. It is an agonist at KISS1R, the class A G-protein-coupled receptor that most of the older literature still calls GPR54. Two features make this listing unusual in a research catalog. The first is that one gene product carries two large and almost entirely separate bodies of published work, one in tumor-metastasis biology under the name metastin and one in neuroendocrinology under the name kisspeptin, so a literature search on either term returns both and the two are routinely cross-cited by people who have not noticed. The second is that the C-terminal amide on this peptide is not a stability refinement but a requirement for receptor activation, which makes the single most consequential identity question for this material a mass difference of roughly one unit. Everything below describes the published research record and the behavior of the material on a bench.
The naming is worth telling properly, because it explains why the literature on this molecule is split in a way that catches people out.
In 1996 a group working at the Penn State College of Medicine in Hershey, Pennsylvania was comparing metastatic and non-metastatic melanoma cell lines and looking for genes whose expression tracked the loss of metastatic capacity. They found one, and transfecting it into metastatic cells suppressed metastasis in their model without suppressing growth of the primary tumor. They called it KiSS-1. The SS stood for suppressor sequence. The Ki was a nod to Hershey Kisses, the product made in the town where the work was done. That is the entire etymology, and it is a genuinely useful thing to know, because nothing in the name signals anything about the reproductive axis.
For five years the gene had no known receptor and no known peptide product. In 2001 several groups independently identified the endogenous ligand of the orphan receptor GPR54 and traced it back to KISS1. One of those groups, working from the anti-metastatic phenotype, named the 54-residue product metastin. That name is still in use, and it is the name under which a substantial part of this compound family appears in oncology journals.
The reorientation came in 2003, from human genetics rather than from peptide chemistry. Two groups reported independently that loss-of-function variants in the gene encoding GPR54 segregated with a form of hypogonadotropic hypogonadism, meaning the reproductive axis failed upstream of the pituitary. That finding turned an obscure metastasis-suppressor gene into a central node in neuroendocrinology essentially overnight, and the subsequent decade of work on hypothalamic kisspeptin neurons grew out of it.
The practical consequence for anyone reading around this material is that two literatures with different assay conventions, different working concentration ranges, different model systems and different vocabulary describe the same gene product. Citations from one are frequently imported into the other without comment. Read the methods, not the abstract, when deciding whether a paper is about the molecule you have.
The sequence, formula and mass for this listing are printed in the specification table further down this page and are not restated here. What is worth interpreting is why the ten residues are the ten residues they are, and why one terminal modification carries more weight on this molecule than on almost anything else in this catalog.
The KISS1 precursor is processed to a 54-residue peptide and to shorter forms conventionally written as kisspeptin-14, kisspeptin-13 and kisspeptin-10. All of them share an identical C-terminal decapeptide, and that decapeptide is the receptor-binding business end. Kisspeptin-10 is therefore not an analog or a designed fragment in the way that, say, a truncated growth-hormone-releasing peptide is. It is the conserved active core with everything else removed. Truncating further, into the C-terminal octapeptide and shorter, degrades activity sharply, which is the usual way of saying that the decapeptide is close to the minimum unit the receptor will read.
The terminal two residues are arginine and phenylalanine, and the phenylalanine carries a C-terminal amide. Arg-Phe-NH2 is the defining motif of the RFamide peptide family, and in this family the amide is load-bearing rather than protective. Removing it, which converts the peptide to the free acid and adds a single negative charge at the position the receptor pocket reads most closely, essentially abolishes agonist activity. A free-acid preparation of this sequence is not a slightly weaker kisspeptin-10. It is a different and largely inert compound that differs in mass by about one unit. In cells, the amide is installed enzymatically from a glycine-extended precursor; on solid phase it comes from the choice of resin, which is why the distinction is a synthesis decision and not a purification artifact.
The rest of the composition is unusually aromatic for a short peptide. There is a tryptophan, a tyrosine at the N-terminus and two phenylalanines, against a single arginine and no acidic side chains at all. That combination makes the peptide net positive at neutral pH, gives it a genuine absorbance at 280 nanometers, and makes it considerably more hydrophobic than its length suggests. There is also a glycine-leucine bond in the middle of the sequence, which matters because it is where matrix metalloproteinases cut, a point taken up under solution behavior below.
KISS1R is a class A, rhodopsin-like G-protein-coupled receptor. Its orphan designation GPR54 remains in wide use and appears in most of the foundational papers, along with the older aliases AXOR12 and hOT7T175 from the deorphanization work. Coupling is through Gq/11, so the canonical readout chain is phospholipase C-beta activation, hydrolysis of membrane phosphatidylinositol bisphosphate to inositol trisphosphate and diacylglycerol, release of calcium from intracellular stores, protein kinase C activation and downstream phosphorylation of ERK1/2. Anything you build to read this receptor in a recombinant cell line is therefore a calcium mobilization assay, an inositol phosphate accumulation assay or a phospho-ERK readout, not a cyclic AMP assay. Researchers arriving from the class B secretin-family peptides in the rest of this catalog, where cyclic AMP is the default endpoint, get this wrong often enough to be worth stating plainly.
The anatomical point is the one that actually distinguishes this compound. KISS1R is expressed on gonadotropin-releasing hormone neurons in the hypothalamus, on their cell bodies and terminals. Kisspeptin therefore acts on the neurons that release GnRH, not on the pituitary cells that respond to GnRH. That places it one level above where GnRH itself and every GnRH analog act. The functional consequence is concrete rather than semantic: a pituitary preparation, a gonadotrope cell line or an isolated pituitary will not reproduce the readout, because the receptor that matters is upstream and absent from those preparations. Any experimental design that expects a kisspeptin effect at the pituitary level is testing something other than the canonical pathway.
The kisspeptin-expressing neurons themselves sit in defined hypothalamic populations, most notably an arcuate nucleus population that co-expresses neurokinin B and dynorphin, referred to in the literature by the compact and now standard label KNDy, and a second population in the preoptic and periventricular region. The arcuate population is where much of the work on the pulse-generating behavior of the axis has concentrated, and steroid feedback onto these two populations runs in opposite directions, which is one of the reasons results are so sensitive to the model, the sex and the endocrine state of the animal.
Expression is not confined to the brain. KISS1 transcript is abundant in placenta, and KISS1R has been reported in pancreas, vasculature and a range of tumor cell lines. A cell background chosen without checking for endogenous KISS1R is a recurring source of confusing baseline signal.
The published record divides into four strands, and the strand a citation comes from determines almost entirely whether it is useful to you.
The first is receptor pharmacology in recombinant systems. Cells expressing human KISS1R, read by calcium mobilization, inositol phosphate accumulation or ERK phosphorylation, with kisspeptin-10 and the longer forms compared against each other and against truncated and free-acid variants. This is the strand that established the amide requirement and the minimum active length, and it is the strand a bench protocol should cite.
The second is neuroendocrine work in rodents and in non-human primates: electrophysiology of GnRH neurons, hypothalamic explants, measurement of downstream gonadotropin release, and the genetics of KISS1R loss of function. Species differences here are real and are discussed under structure and in the questions below.
The third strand is unusual for a compound in this catalog. There is a substantial published human physiology literature, much of it from a group at Imperial College London and from several other academic centers, in which kisspeptin-10 and kisspeptin-54 were given to volunteers under research protocols and circulating gonadotropin concentrations were measured. Studies of that kind compared the two peptide lengths directly, compared bolus against continuous exposure, and examined how the response varies with endocrine state. It is genuinely rare to have human comparative pharmacology for a research peptide, and it is the reason the kisspeptin-10 versus kisspeptin-54 distinction is better documented here than analogous distinctions are for most peptide families. None of that work says anything about this vial, and none of it transfers to any use in people or animals; it is cited here as literature, and nothing more.
The fourth strand is the oncology literature under both KISS1 and metastin. Its endpoints are migration and invasion assays, anchorage-independent growth, expression correlation across tumor sample series and, in some reports, focal adhesion and cytoskeletal readouts. The concentrations used, the exposure durations and the cell backgrounds bear no relation to the neuroendocrine work.
One phenomenon spans strands two and three and deserves naming because it is misread so often. Continuous exposure to kisspeptin produces desensitization of the axis, whereas intermittent or pulsed exposure does not, and the two protocols can give opposite-looking readouts from the same compound. This is the same shape of result that made continuous GnRH agonist exposure a suppressive rather than a stimulatory manipulation, and the parallel is not a coincidence.
The most common error in secondary discussion of this compound is treating kisspeptin-10 and kisspeptin-54 as the same reagent. They share the entire receptor-binding decapeptide, they act at the same receptor, and their in vitro potencies are broadly comparable. Their behavior in a living system is not comparable, because clearance differs substantially: the shorter peptide is cleared on the order of a few minutes and the longer one persists several times longer. A conclusion drawn from a bolus of kisspeptin-54 about the duration or shape of a response cannot be carried over to kisspeptin-10, and a great deal of vendor-facing and review-level writing does exactly that without flagging which peptide was used. When a source says only kisspeptin, treat the number as unusable until you can find the length in the methods.
The second recurring problem is cross-importation between the two literatures. Papers reporting that KISS1 expression suppresses metastasis in a melanoma or breast model are cited as though they supported claims about the reproductive axis, and the reproductive genetics is cited as though it established a mechanism in tumor biology. These are the same gene product in radically different systems. Worse, the tumor literature is itself not unidirectional. While the founding work identified KISS1 as a metastasis suppressor, later reports in some tumor types, notably certain breast cancer models, describe KISS1R signaling as promoting rather than restraining invasion. That is an unresolved contradiction in the field, not a settled story, and any source that presents metastin as straightforwardly anti-metastatic is oversimplifying.
Third, selectivity within the RFamide family is under-reported. Kisspeptin shares its C-terminal motif with RFRP-1 and RFRP-3, prolactin-releasing peptide, QRFP and the neuropeptide FF group, and their receptors are structurally related. At the low concentrations typical of a well-designed receptor assay this is not a problem. At the high concentrations often used in tissue and whole animal work it can be, and few papers include the counter-screening that would exclude it.
Fourth, species sequence differences at the C-terminus are frequently ignored when reagents from one species are applied to tissue from another.
Kisspeptin-10 is supplied lyophilized, and its solution behavior is set by two things that pull in opposite directions: it is a basic peptide with no acidic side chains, and it is unusually aromatic for its length.
The basic character means the peptide carries a net positive charge across the useful pH range and generally goes into aqueous solution without needing an organic co-solvent, with slightly acidic water dissolving it more readily than neutral water. The aromatic content, one tryptophan, one tyrosine and two phenylalanines out of ten residues, means it is more hydrophobic than a decapeptide usually is, and hydrophobic short peptides adsorb to container surfaces and to pipette tips. The loss is worst in dilute solution in a large-surface-area vessel, which is precisely the condition of a working dilution for a cell assay. Low-binding labware and a minimum number of transfer steps matter here more than the peptide length would lead you to expect.
Two residues carry specific chemical liabilities. Tryptophan oxidizes, faster under light and with trace metals present, giving products separated from the parent by small mass increments. Keep solutions dark for that reason alone. The two asparagines deamidate, and the asparagine followed by serine is a known fast pair for that reaction, slowly converting a neutral side chain to an acidic one and producing a species that chromatographs close to the parent.
The behavior most worth understanding is proteolytic. Matrix metalloproteinases cleave kisspeptins at the glycine-leucine bond in the C-terminal region, and this is the principal reason the plasma half-life is short. The bench consequence is a sharp divergence between in vivo and in vitro behavior. In a clean serum-free buffer the peptide is stable enough to run a plate assay against. In serum-supplemented culture medium, or in anything containing active metalloproteinase, it is being cut during the incubation, and the fragments left behind do not activate the receptor because the cut removes part of the essential C-terminal core. Long incubations in serum-containing medium therefore under-report activity for reasons that have nothing to do with the receptor.
A degraded solution announces itself as loss of optical clarity or faint wisps rather than as gross precipitate. Freeze-thaw cycling accelerates all of this. The storage statement in the specification table above is the product record for this material and should be read alongside the documentation supplied with the lot.
The single analytical question that matters most for this material is whether the C-terminus is the amide or the free acid, and it is a harder question than it looks because the difference is roughly one mass unit on a decapeptide.
Nominal-resolution mass spectrometry will not settle it. The amide and the free acid differ by less than the width of the isotope spacing that a low-resolution instrument reports, and on a doubly charged ion the separation is halved again. What settles it is either accurate mass at adequate resolving power, where the difference is unambiguous against the theoretical value, or tandem mass spectrometry, where the C-terminal fragment ion carries the modification directly and the free acid form shifts that fragment while leaving the N-terminal series unchanged. Chromatography alone is weak evidence: the free acid is slightly more polar and elutes near the amide, close enough that a generic fast gradient will not resolve the two, so a shallow gradient or a change of ion-pairing conditions is needed if separation is the goal. Since the free acid arises from a resin choice at the start of synthesis rather than from degradation in the vial, it is present or absent as a bulk property of the lot, not as a trace impurity that grows over time.
The composition helps in two other ways. The tryptophan and tyrosine give the peptide a real absorbance at 280 nanometers, so concentration in solution can be checked spectrophotometrically, which is not possible for the aliphatic short peptides elsewhere in this catalog. The single arginine protonates readily and produces a strong positive-mode electrospray signal, usually dominated by the doubly charged ion, with a clean fragment series in tandem mode.
Two caveats attach. Amino acid analysis is a poor identity tool for this sequence specifically: acid hydrolysis destroys tryptophan and converts both asparagines to aspartate, so the analysis cannot see one residue at all and reports two others as something they are not. And because the peptide is basic, it is normally isolated as a trifluoroacetate salt, so the mass in the vial includes counter-ion and water. Net peptide content is a separate measurement from both purity and identity, and it is the one most often missing.
| Often mistaken for | How it actually differs from Kisspeptin-10 |
|---|---|
| hCG | Not comparable in any structural sense and not comparable in mechanism either. hCG is a heterodimeric glycoprotein hormone, not a synthetic peptide, and it acts at LHCGR on the gonad, which is the bottom of the same axis. Kisspeptin-10 acts at the top of it, on hypothalamic neurons. The two are separated by two intervening signaling steps and by an entire class of receptor. |
| PT-141 (bremelanotide) | Grouped with kisspeptin in popular writing because both get described as reproductive, which is where the similarity ends. Bremelanotide is a cyclic melanocortin analog derived from the alpha-MSH lineage and acts at melanocortin receptors, a different class A receptor family with different coupling and a different anatomy. No shared sequence motif, no shared receptor, no shared literature. |
| Kisspeptin-54 (metastin) | The longer product of the same precursor, containing the identical C-terminal decapeptide. Comparable at the receptor, not comparable in a living system: it is cleared several times more slowly, so the shape and duration of any downstream response differs. It is also the form under which most of the oncology literature was published, under the name metastin. |
| GnRH (gonadorelin) | Also a decapeptide, also acting on the reproductive axis, and one level downstream. GnRH acts at GnRHR on pituitary gonadotropes. Kisspeptin acts on the GnRH neurons themselves. A preparation containing pituitary cells but no hypothalamic neurons will respond to one and not the other, which makes the two useful as controls for each other rather than as substitutes. |
| Triptorelin | A GnRH superagonist. It is worth naming next to kisspeptin-10 because it is the textbook case of the same phenomenon: pulsed exposure drives the axis, continuous exposure desensitizes it and gives the opposite readout. Kisspeptin shows the same continuous-versus-pulsed behavior, and papers are misread in exactly the same way as a result. |
| RFRP-3 (GnIH), NPFF and other RFamide peptides | A family sharing the C-terminal Arg-Phe-amide motif and a set of structurally related receptors, including GPR147, GPR74, GPR10 and GPR103. Selectivity is good at low concentrations and becomes a genuine question at the high concentrations common in tissue work. Counter-screening against the related receptors is the control that most published work omits. |
They are products of the same gene. Metastin is the name given to the 54-residue peptide by the group that identified it from its anti-metastatic activity, and it is still the common name in the oncology literature. Kisspeptin is the name that took hold in neuroendocrinology. Kisspeptin-10 is the C-terminal decapeptide shared by metastin and by every other length in the family, so it is a fragment of metastin rather than a synonym for it. The practical point for searching the literature is that the two terms retrieve largely non-overlapping sets of papers with different endpoints, different concentration ranges and different model systems, and a source that mixes them without comment should be read carefully.
Because in the RFamide family the amide is part of the recognition motif rather than a stability modification. The receptor pocket reads the terminal arginine and phenylalanine closely, and converting the amide to a free acid introduces a negative charge exactly there. The published structure-activity work reports that the free-acid form is essentially inactive as an agonist, which is a much larger consequence than amidation carries on most peptides, where it mainly slows carboxypeptidase attack. The awkward part is that the two forms differ by about one mass unit, so a certificate reporting an intact mass at nominal resolution does not distinguish them. That is the identity question worth asking about this specific material.
No, and the distinction is the main conceptual point about this compound. KISS1R is expressed on hypothalamic GnRH neurons, so kisspeptin acts on the neurons that release GnRH. Pituitary gonadotropes then respond to the GnRH those neurons release, through a different receptor. Kisspeptin therefore sits one level above where gonadorelin, triptorelin and every other GnRH analog act. This has a direct experimental consequence: an isolated pituitary preparation or a gonadotrope cell line has no reason to respond, because the relevant receptor is not there. Designs that expect a pituitary-level effect are measuring something other than the canonical pathway, and any signal they find needs a different explanation.
The C-terminal residue is not conserved across species. The human sequence ends in phenylalanine, giving the classic RF-amide terminus, while the mouse sequence ends in tyrosine, giving an RY-amide. It is a single conservative aromatic substitution and both forms are active at their own receptors, but the receptor is also not identical across species, so cross-species reagent use is not automatically safe. The honest position is that it is usually tolerated and occasionally is not, and that reported potency differences between studies using human and rodent peptide on the same tissue can come from this rather than from anything biological. If the comparison matters, run both peptides in the same assay rather than comparing across papers.
Because sustained agonist occupancy at this receptor produces desensitization, which is a property of the system rather than an artifact. The published record describes the axis becoming progressively less responsive under continuous kisspeptin exposure while remaining responsive to intermittent exposure. This is the same shape of finding that made continuous GnRH agonist exposure a suppressive manipulation rather than a stimulatory one. It means the exposure protocol is not a minor methodological detail, and that two papers reporting opposite directions of effect may both be correct and simply not be describing the same experiment. Whenever a kisspeptin result is quoted without the exposure pattern attached, the number is close to uninterpretable.
At the receptor, largely yes, since they share the entire binding decapeptide. In any intact system, no. Clearance differs substantially: the decapeptide is cleared on the order of minutes, largely through metalloproteinase cleavage at an internal bond, while the 54-residue form persists several times longer. That difference changes the magnitude, the duration and the shape of any downstream readout, and it is why comparative studies of the two lengths were done at all. A paper that reports only kisspeptin without stating the length is not usable as a quantitative reference, and the conflation of the two is the single most common error in secondary writing about this family.
A calcium mobilization assay in a recombinant line reports that the Gq pathway was engaged, which is necessary but not sufficient. Two additions are worth the effort. The first is a selectivity counter-screen against the related RFamide receptors, because the shared C-terminal motif makes cross-reactivity a real possibility at higher concentrations and very little published work excludes it. The second is a readout further down the same pathway, inositol phosphate accumulation or ERK phosphorylation, run in parallel, because agreement between a proximal and a distal endpoint is much harder to produce by artifact than either alone. A binding measurement using a labeled ligand adds a third, independent axis.
The section above covers what KissPeptin-10 is and what the published literature has looked at. This section is the operational half: what physically arrives when you order this listing, what paperwork comes with it, which fields on that paperwork are worth reading closely, and how to log the material once it is on your bench. It is written for the person who has already decided the compound is relevant and now has to justify the purchase to a supervisor, a grant line or an internal quality process.
Everything below is scoped to this exact listing rather than to research peptides in general. If you want the general version — how to read a certificate of analysis from scratch, what HPLC and mass spectrometry each prove, how to compare two suppliers who both claim 99% — that is on the home page guide, and there is no reason to read it twice.
One sealed vial of lyophilized material at the listed 10 mg fill, labeled for research use only, dispatched within 24 hours of the order clearing. Batch documentation is available for the lot you receive. Free shipping applies at $150 and above.
This listing is a single fixed presentation, not a size selector. That is deliberate: each presentation gets its own page, its own documentation trail and its own URL, so a citation or a purchase-order line that points at KissPeptin-10 at 10 mg points at exactly one thing. If you need a different fill of the same compound and it is not listed, it is not currently in stock rather than hidden behind a dropdown.
| Field | This listing |
|---|---|
| Listing | KissPeptin-10 10 mg |
| Labeled fill mass | 10 mg |
| Physical form | Lyophilized powder in a sealed vial |
| Catalog category | Melanocortin & Reproductive Peptides |
| Compound class | Reproductive-axis research peptide |
| Intended use | Research use only. Not for human or veterinary use, not for diagnostic use, not a drug or supplement. |
| Dispatch | Within 24 hours of the order clearing |
| Documentation | Batch analytical documentation available for the lot supplied |
| Free shipping threshold | Orders of $150 and above |
The table below is the specification the store publishes for this listing. It is reproduced here from the product record itself rather than retyped, which means it cannot drift away from what the attribute table further up the page says. Where a field is absent it is absent because we do not publish it for this SKU, not because it was left out of this summary.
| CAS No. | 374675-21-5 |
| Purity | ≥99% |
| Sequence | Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 |
| Molecular Formula | C63H83N17O14 |
| Molecular Weight | 1302.46 g/mol |
| Synthesis | Solid-phase synthesis |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Applications | KISS1R signaling research, reproductive endocrinology studies, GnRH regulation models |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
A specification table is a claim, and a claim is only worth the record behind it. Every field above is one you can ask us to substantiate against the batch documentation for the lot you were sent. If a field ever fails to match the paperwork, that is a defect on our side and we would rather hear about it than not.
Materials in this group are usually supplied as a defined fragment of a longer parent peptide, and the fragment boundaries are part of the identity. A name without a fragment designation is an incomplete specification.
A certificate of analysis is not a quality badge. It is a measurement report about one specific batch, produced on a specific date by a specific method, and its value to you is entirely a function of how much of that context it discloses. For KissPeptin-10 the fields worth checking first are the ones that tie the document to the container in your hand.
| Field on the certificate | Why it matters for this SKU |
|---|---|
| Lot or batch identifier | Ties the document to the vial. A certificate with no lot reference describes some batch, not necessarily yours. |
| Compound name and, where applicable, sequence | This is the identity claim. For a reproductive-axis research peptide it is the field that distinguishes the material from its close relatives. |
| Analytical method and conditions | A purity figure without a method is a number without units. Column, gradient and detection wavelength change what the figure means. |
| Date of analysis | Establishes how old the measurement is relative to the material. A recent vial with a two-year-old certificate is a documentation gap. |
| Who performed the analysis | In-house and independent third-party results are both legitimate; they are not the same claim, and the document should say which it is. |
| The chromatogram or spectrum itself | A summary table can be typed by anyone. A trace can be read, and a reader who knows the compound class can tell whether it is plausible. |
What our documentation for KissPeptin-10 does assert is what the analysis measured on the batch that was tested. What it does not assert — and no certificate from any supplier can assert — is that the material is safe, that it is suitable for any use in humans or animals, or that it will reproduce a result reported in a published paper. Those are different questions and a purity figure is not evidence for any of them.
Our batch documentation policy, including how to request the record for a lot you already have, is on the certificate of analysis page. If you need the record before ordering rather than after, ask us through the contact page and reference this listing by name.
Three questions have to be answered separately before a compound gets a page here, and collapsing them into one percentage is the most common way a supplier listing becomes misleading.
| Question | What answers it | What it does not tell you |
|---|---|---|
| Identity — is this the right molecule? | Mass determination, and sequence confirmation where the material is a defined chain | Nothing about how much of the vial is that molecule |
| Purity — what proportion of the detected material is the target? | Chromatographic separation with a stated method | Nothing about what the other fraction actually is, unless the impurities are themselves identified |
| Content — how much target material is actually in the container? | Quantitative determination against the labeled fill | Nothing about identity or purity; a vial can be accurately filled with the wrong thing |
For KissPeptin-10, receptor binding studies and hypothalamic or pituitary explant work are the assay formats the published work in this area tends to use, which matters when you are deciding whether the material as supplied is fit for the experiment you have in mind. A compound that is clean enough for a binding assay is not automatically clean enough for a quantitative cell-based readout where a co-eluting impurity could carry activity of its own.
Content is the field most often missing from a supplier listing, and it is the one that changes your arithmetic. A vial labeled 10 mg contains that much total solid, and total solid includes counter-ion, residual water and whatever else survived the process. If you need the peptide mass rather than the vial mass to be exact, that is a specific request to make in advance, not an assumption to carry into a calculation.
The most useful five minutes you will spend on this material are the five minutes immediately after the package is opened, because that is the only moment at which you can still distinguish a transit problem from a handling problem of your own.
Fragments in this class are supplied at low fill masses, so the vial is easier to under-recover than to over-recover.
The general rule for lyophilized material is that the dry state is the stable state and every transition away from it costs you something. Freeze-thaw cycling is the specific mechanism most likely to degrade KissPeptin-10 after it reaches you, and it is entirely under your control: a single reconstitution split into pre-planned aliquots exposes the material once, while repeatedly warming and refreezing one container exposes it as many times as you open it. There is a fuller treatment of the mechanism in our guide on freeze-thaw cycles in peptide research materials and on storage and handling.
This is arithmetic, not guidance. The only thing the table below does is tell you what concentration you are holding after you have added a known volume of diluent to a vial labeled 10 mg, so that the figure in your notebook and the figure in the container are the same figure. It says nothing about how much material any experiment should use, and it is not applicable to any use in humans or animals.
| Diluent added | Resulting concentration | Amount in 0.1 mL | Amount in 0.05 mL | Aliquots of 0.25 mL |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 1,000 µg | 500 µg | 4 |
| 2 mL | 5 mg/mL | 500 µg | 250 µg | 8 |
| 3 mL | 3.33 mg/mL | 333.3 µg | 166.7 µg | 12 |
| 5 mL | 2 mg/mL | 200 µg | 100 µg | 20 |
Every figure above is the same division: the labeled mass of KissPeptin-10 divided by the volume of diluent added. Nothing in the table is a recommendation about how much material to use in an experiment — it is the arithmetic that tells you what concentration you are holding once you have added a known volume, so that the number you write in the notebook matches what is in the container.
Two things routinely go wrong at this step. The first is treating the labeled mass as the peptide mass; as noted above, the labeled figure is total solid unless the documentation says otherwise, so a concentration derived from it is a nominal concentration. Say so in your methods rather than implying a precision the specification does not support. The second is ignoring the volume the solid itself occupies — small at these masses, but not zero, and it means the final volume is very slightly greater than the volume you added.
If you want to work backwards from a target concentration to a diluent volume, or to check a figure against a different vial size, our peptide reconstitution calculator does the same division in both directions and shows its working.
Reproducibility in this area fails at the material-provenance step far more often than at the analysis step. The fields below are the ones that let somebody else — a reviewer, a collaborator, or you in eighteen months — work out whether two sets of results were generated with comparable material.
Comparing KissPeptin-10 across suppliers on price alone is comparing two numbers that may not describe the same thing. These are the questions that make the comparison meaningful, with our answers next to them so you can hold us to the same standard you would hold anyone else.
| Question to ask any supplier | Our answer for this listing |
|---|---|
| Is batch documentation available for the specific lot I will receive, not a representative lot? | Yes — the record is tied to the lot supplied. Policy on the certificate of analysis page. |
| Does the analytical method appear on the document, or only the result? | The method context belongs on the document; a bare percentage is not a complete record. |
| Is the labeled figure total solid or target-compound mass? | Labeled as the fill for this presentation. If you need the distinction resolved for a calculation, ask before ordering. |
| Is the listing labeled research use only throughout, without use claims? | Yes, and deliberately so. No use, benefit or outcome is claimed anywhere on this page. |
| How quickly does it dispatch, and is that a promise or an average? | Within 24 hours of the order clearing. |
| Can I reach a person about the paperwork rather than only about the order? | Yes — the contact page reaches us directly. |
| Is there a published position on what the documentation does not prove? | Yes. It is stated on this page and on every product page. |
A supplier who answers all seven honestly is a better bet than a supplier who is ten percent cheaper and answers four. A supplier who cannot answer the first one at all is not selling you documented material; they are selling you a container.
KissPeptin-10 is supplied for laboratory research use only. It is not a drug, not a supplement, not a cosmetic and not a medical device. It is not for human or veterinary administration, not for diagnostic use, and not for use in food. That is not a disclaimer bolted onto a sales page — it is the actual scope of what is being sold, and it constrains what can honestly be written about it.
| Language that stays inside the boundary | Language that does not |
|---|---|
| "Supplied for research use only" | Any phrasing that implies a personal or clinical use |
| "Published work in this area has examined receptor engagement and upstream endocrine signaling in reproductive-axis models" | "KissPeptin-10 does X" stated as an established effect |
| "Purity determined by the stated method on the tested batch" | "Pharmaceutical grade", "medical grade", "safe" |
| "Concentration arithmetic for preparing laboratory aliquots" | Anything framed as a dose, a protocol or a schedule |
| "Not for human or veterinary use" | Silence on the point, which readers correctly interpret as evasion |
| Naming the model system a finding came from | Reporting an animal or in-vitro finding as though it were a human finding |
The reason to be precise about this is not only regulatory. Research literature on this class of material is genuinely interesting and genuinely incomplete, and overstating it makes the real findings harder to see. Where published work is referenced on this site it is referenced as what was measured, in what system, at what scale — not as a property of the vial.
These share a catalog category with KissPeptin-10, which means the documentation and handling considerations above largely transfer to them. Their compound-specific sections do not — each has its own identity, its own literature and its own analytical profile.
| Listing | Price |
|---|---|
| HCG 5000 IU | Original price was: $55.99.$49.99Current price is: $49.99. |
| PT-141 (Bremelanotide) 10 mg | Original price was: $33.99.$29.99Current price is: $29.99. |
The full catalog is on the shop page, and the longer written material is in our research guides.
Yes. Ask through the contact page and reference this listing by name. Our general position on batch documentation is on the certificate of analysis page. If a supplier will not show you the record until after payment has cleared, that is worth noticing.
It is the labeled fill for this presentation. For lyophilized material the labeled mass is total solid unless the documentation states otherwise, and total solid includes counter-ion and residual moisture as well as target compound. If your calculation depends on the distinction, resolve it against the batch record rather than assuming.
Within 24 hours of the order clearing. Orders of $150 and above ship free. Transit time after dispatch depends on the service selected at checkout.
No. This material is supplied for laboratory research use only. It is not a drug, supplement or cosmetic, it is not for human or veterinary administration, and nothing on this page should be read as guidance for any such use.
Store the sealed vial dry, dark and at the temperature stated for this listing, and record the date it entered storage. Once material is in solution the useful discipline is to minimize repeated warming: plan the aliquot scheme before the first reconstitution so the material is exposed once rather than once per experiment. Fragments in this class are supplied at low fill masses, so the vial is easier to under-recover than to over-recover.
That depends entirely on the concentration your protocol calls for, which is your decision and not something a product page can answer. What the table above provides is the arithmetic: labeled mass divided by added volume gives concentration. The reconstitution calculator runs the same division in either direction.
No, and this is the single most common misreading of a certificate of analysis. Purity describes what proportion of the detected material was the target compound in the batch that was tested, by the method stated. It is not a safety assessment, it says nothing about suitability for any use in humans or animals, and it does not become a safety claim by being a large number.
It is listed as a defined fragment of a longer parent peptide, in the Melanocortin & Reproductive Peptides category. Published work in this area has looked at receptor engagement and upstream endocrine signaling in reproductive-axis models. That is a description of where the literature sits, not a claim about what the material does.
Yes. The home page guide covers reading a certificate of analysis, what chromatographic and mass-spectrometric methods each prove, and how to compare suppliers. The research guides go deeper on individual topics, and the FAQ covers ordering, shipping and post-shipping questions.
KissPeptin-10 10 mg is supplied strictly for laboratory research use. It is not a drug, supplement, cosmetic or medical device; it is not for human or veterinary use, not for diagnostic use and not for use in food. No statement on this page is intended to describe a therapeutic use, benefit or outcome, and references to published work describe what was measured in the reported model system rather than a property of the material supplied. Purchasers are responsible for handling the material in accordance with the requirements applicable to their institution and jurisdiction.
Our batch documentation policy is published in full, and the reconstitution arithmetic for this vial is one click away. Certificate of analysis policy · Reconstitution calculator · Full catalog
